Urologists, not feds, must develop quality measures

Article

If we do not develop our own performance measures, someone else will do it for us.

Over the past 5 years, a number of organizations such as the Leapfrog Group have stated that the "quality" of medicine leaves much to be desired. The Institute of Medicine's statement several years ago (extrapolated from data from a handful hospitals) that between 48,000 and 96,000 patients in the United States die from medical errors per year made headlines and caused a stir.

The current hot medical topic in Washington and the private insurance industry is pay for performance, also known as P4P. Simply stated, Medicare has proposed paying providers more if they meet certain "quality measures."

In February, I had the honor to be asked to testify before the House Ways and Means Subcommittee on Health on behalf of the AUA and 12 other specialties representing over 200,000 specialty physicians. Some of the points I made to the committee were:

So what is P4P in a urology practice? Like other specialties, AUA has established a workgroup to investigate and consider what are realistic and appropriate quality performance measures for a urologist. This might be something as simple as demonstrating that a urologist adheres to published AUA guidelines, but how to report this to CMS remains unclear.

I cannot tell you at this time what this will ultimately look like. But I can tell you that if we do not develop our own performance measures, someone else will do it for us.

Related Videos
Kevin M. Wymer, MD
Video 7 - "Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer"
Video 6 - "Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape"
Video 5 - "Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer"
Video 4 - "Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis"
Video 3 - "Treatment Selection in Metastatic and Castration Resistant Prostate Cancer: Optimizing Outcomes and Preserving Patient Quality of Life"
Video 2 - "Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer"
Video 1 - "Metastatic Prostate Cancer: Background and Patient Prognosis"
Related Content
© 2024 MJH Life Sciences

All rights reserved.